Pancreatic adenocarcinoma

This early-phase study tests a new drug called AB680, combined with immunotherapy (zimberelimab) and two chemotherapy drugs (nab-paclitaxel and gemcitabine), in people with advanced pancreatic cancer that has spread. The main goals are to check safety and find the right dose. Abo…

This study tests whether giving higher doses of radiation, guided by MRI, can help people with pancreatic cancer that cannot be removed by surgery. Participants must have already had several months of chemotherapy without the cancer spreading. The goal is to see if this approach …

This study tested two different treatment plans for people with a specific type of pancreatic cancer that is on the edge of being removable by surgery. 130 patients received either chemotherapy alone or chemotherapy plus radiation before surgery. The goal was to see which approac…

This study tests a 3-week course of radiation (using photons or protons) combined with chemotherapy for people with pancreatic cancer that hasn't spread. The goal is to see if this shorter treatment is safe and effective, either before surgery or as the main therapy. Researchers …

This trial is testing whether adding an experimental antibody called XB2001 to a standard chemotherapy regimen can help people with advanced pancreatic cancer. The study has two parts: first, it finds the safest dose of XB2001, then it compares the antibody plus chemo against a p…

This trial is testing whether adding high-dose vitamin C (ascorbic acid) to a standard three-drug chemotherapy cocktail can safely and effectively control metastatic pancreatic cancer in people who have not yet received any treatment. The study enrolls adults with stage IV pancre…

This early-phase trial tests two drugs together in 15 people with advanced pancreatic cancer. One drug, calaspargase pegol-mknl, lowers a nutrient that cancer cells need to grow. The other, cobimetinib, blocks a protein that helps cancer cells survive. The goal is to find a safe …

This phase II trial tests whether adding high-dose vitamin C (ascorbate) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with metastatic pancreatic cancer live longer. About 40 participants are randomly assigned to receive either standard chemo alone or …

This phase II trial tests whether a combination of four chemotherapy drugs—paclitaxel protein bound, gemcitabine, cisplatin, and hydroxychloroquine—given before surgery can improve outcomes for people with pancreatic cancer that has not spread. The study focuses on patients whose…

This study tests a treatment plan for people with advanced pancreatic cancer that has spread to a major artery. Participants receive chemotherapy and radiation before surgery, then more chemo after. The goal is to see if this approach is safe and helps patients live longer. The t…

This early-phase study tested a new treatment using immune cells from cord blood, modified to target a protein called Claudin18.2 found on some cancer cells. Ten adults with advanced stomach or pancreatic cancer who had no other options received these cells to find the safest dos…

This study tests a new drug called pegilodecakin, a lab-made version of a natural immune protein (interleukin-10), in people with advanced solid tumors such as melanoma, lung, breast, prostate, ovarian, kidney, colorectal, and pancreatic cancers. The drug is given as a daily shot…

This study tests whether a special hand therapy program can prevent chemotherapy-induced nerve damage in the hands of people with pancreatic cancer. Participants are randomly assigned to either the hand therapy or traditional occupational therapy. The goal is to see if the hand t…

This early-phase study tests whether adding losartan (a blood pressure medicine) to a shorter, higher-dose radiation treatment can help people with pancreatic cancer that is hard to remove surgically. The main goal is to check for side effects and find the safest dose. About 22 a…

This trial investigates whether adding antroquinonol (Hocena) to standard chemotherapy (nab-paclitaxel and gemcitabine) can safely treat people with metastatic pancreatic cancer that has not yet been treated. The study has two phases: first, finding the best dose, and second, che…

This trial tested a new treatment called EGFR BATs for people with advanced pancreatic cancer. The treatment uses a patient's own immune cells, armed with a special antibody, to target cancer cells. The study included 22 participants who had already received chemotherapy. The goa…

This completed phase 1/2 trial tested an experimental drug called Y101D combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for 71 people with advanced pancreatic cancer. The goal was to find a safe dose and see if the combo helps shrink tumo…

This early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…

This phase 2 trial tested whether adding the drug veliparib to standard chemotherapy (FOLFIRI) helps people with metastatic pancreatic cancer live longer. 123 patients whose cancer had returned after initial treatment were randomly assigned to get FOLFIRI alone or FOLFIRI plus ve…

This phase 2 trial tested a combination of four chemotherapy drugs—irinotecan liposome, oxaliplatin, 5-fluorouracil, and levoleucovorin—in 41 Japanese adults with metastatic pancreatic cancer who had not received prior treatment. The goal was to see how well the drugs shrank tumo…

This study tested whether adding two experimental drugs (TTX-030 and budigalimab) to standard chemotherapy could help people with metastatic pancreatic cancer live longer without their disease getting worse. 194 adults who had not yet received treatment for their advanced cancer …

This study tested a combination of three chemotherapy drugs (paclitaxel protein bound, gemcitabine, and cisplatin) in 34 people with metastatic pancreatic cancer that had not been treated before. If the cancer got worse, a fourth drug (paricalcitol) was added. The goal was to see…

This phase 1 trial tested a personalized vaccine made from each patient's unique cancer mutations (neoantigens) combined with an immune booster (poly-ICLC) in 33 people with pancreatic cancer. The vaccine was given after standard chemotherapy, either before or after surgery. The …

This study tested a combination of four drugs (tadalafil, pembrolizumab, ipilimumab, and CRS-207) in 17 people with advanced pancreatic cancer that had worsened after at least one round of chemotherapy. The goal was to see if the combination was safe and could shrink tumors. The …

This early-phase study tested a combination of three drugs (gemcitabine, capecitabine, and erlotinib) in 30 people with advanced pancreatic cancer that had already been treated. The main goal was to find the safest dose and understand side effects. This is not a cure, but aims to…

This study tested a combination of four drugs (paclitaxel protein bound, gemcitabine, cisplatin, and paricalcitol) given before surgery to people with pancreatic cancer that could or could not be removed. The goal was to see if the treatment could shrink tumors and improve surgic…

This Phase 3 trial tested a new combination of chemotherapy drugs—irinotecan liposome, oxaliplatin, 5-fluorouracil, and leucovorin—against the standard treatment (nab-paclitaxel plus gemcitabine) in 770 people with metastatic pancreatic cancer who had not received prior chemother…

This study tested a new drug called HCW9218 in 21 people with advanced pancreatic cancer that had stopped responding to standard treatments. The drug is designed to boost the immune system and block a protein that helps tumors grow. The main goals were to check safety and find th…

This early-phase trial tested a new type of radiation called carbon ion therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. Fourteen participants received increasing doses of carbon ion radiation along with chemotherapy. The main goal was…

This study tested a combination of two oral drugs, ribociclib and everolimus, in 12 people with metastatic pancreatic cancer that had stopped responding to standard chemotherapy. The goal was to find the right dose and see if it could slow tumor growth. The trial was small and ea…

This early-phase trial tested two drugs—binimetinib and hydroxychloroquine—in 34 people with a specific type of advanced pancreatic cancer (KRAS-mutant) that had spread. The goal was to find the safest dose of hydroxychloroquine when used with binimetinib, and to see if the combi…

This study tested an experimental immunotherapy called indoximod added to standard chemotherapy (gemcitabine and nab-paclitaxel) in 157 people with metastatic pancreatic cancer. The goal was to find a safe dose and see if the combination helps people live longer. The trial has co…

This early-phase trial tested an experimental oral drug called IOA-289 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in 16 people with metastatic pancreatic cancer. The main goal was to check safety and find the right dose. Researchers also looked at how th…

This study tested a combination of two oral chemotherapy drugs, vemurafenib and sorafenib, in 10 people with advanced pancreatic cancer that has a specific genetic change called a KRAS mutation. All participants had already tried at least two standard treatments without success. …

This study tested a drug called niraparib in 32 people with advanced pancreatic cancer that has certain gene changes (like BRCA). The goal was to see if the drug could slow down or stop the cancer from growing. While not a cure, it offers a targeted treatment option for patients …

This early-stage study tested a new drug called cabotamig in 33 adults with advanced cancers of the digestive system (like colon, pancreas, or liver) that had stopped responding to standard treatments. The goal was to see if the drug is safe and how it affects the body and tumors…

This phase II trial tested a combination of a pancreatic cancer vaccine (GVAX), an immunotherapy drug (pembrolizumab), and focused radiation (SBRT) in 58 patients with locally advanced pancreatic cancer. The goal was to see if this approach could delay the spread of the cancer to…

This phase 2 study tested a combination of three drugs—gemcitabine, trastuzumab, and erlotinib—as a first treatment for people with metastatic pancreatic cancer that has spread. The goal was to see if the combination could control tumor growth. 63 patients received the drugs intr…

This study tested a combination of chemotherapy drugs given both before and after surgery for people with early-stage pancreatic cancer. The goal was to shrink the tumor before surgery and kill any remaining cancer cells afterward. 46 participants were enrolled to see if this app…

This completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…

This large phase III trial tested whether adding the targeted drug erlotinib or chemoradiation to standard chemotherapy after surgery could help people with pancreatic cancer live longer. Over 500 patients who had their tumor removed were randomly assigned to different treatment …

This study tested a drug called romiplostim in 165 adults with gastrointestinal, pancreatic, or colorectal cancer who were receiving chemotherapy. The goal was to see if romiplostim could prevent low platelet counts (thrombocytopenia) that often force doctors to delay or reduce c…

This early-stage study tested whether combining a procedure that uses electrical pulses to destroy tumors (IRE) with an immunotherapy drug (pembrolizumab) is safe for people with locally advanced pancreatic cancer that cannot be removed by surgery. Only 2 participants were enroll…

This phase II trial tested whether adding paricalcitol (a vitamin D drug) and hydroxychloroquine (an autophagy inhibitor) to standard chemotherapy could help shrink tumors in 10 people with advanced or metastatic pancreatic cancer. The goal was to see if the combination improved …

This phase 3 trial tested a wearable device called Tumor Treating Fields (TTFields) combined with standard chemotherapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The device sends low-intensity electric fields to the tumor area to disrup…

This study looked at 211 people with advanced pancreatic cancer whose first treatment (FOLFIRINOX) stopped working or caused too many side effects. Researchers compared a two-drug combination (gemcitabine and paclitaxel) against gemcitabine alone to see if the combo helped people…

This phase II trial tested two chemotherapy combinations as first-line treatment for people with advanced or metastatic pancreatic cancer. One group received a newer regimen called SLOG, while the other got a standard combo called mFOLFIRINOX. The study aimed to see which worked …

This study compared robotic-assisted pancreatic surgery to the standard open approach for people with pancreatic and related tumors. Researchers wanted to see if robotic surgery could help patients recover faster after the operation. A total of 268 patients took part across multi…

This phase 2 trial tested whether a new way of targeting radiation (based on where the cancer usually comes back) works better than the standard method for locally advanced pancreatic cancer. 96 patients received either the new or standard radiation. The study looked at how long …

This early-phase trial tested a new treatment called CTX131 for adults with advanced solid tumors that have not responded to standard therapies. The treatment uses donor immune cells that are gene-edited to target a protein called CD70 found on cancer cells. The study enrolled 19…

This early-phase trial tested a new way to treat advanced cancers that have spread. It combined a special type of radiation with two immunotherapy drugs (MEDI4736 and tremelimumab) to see if the combination is safe and tolerable. The study included 53 adults with advanced melanom…

This study tested several immunotherapy-based drug combinations in 341 people with metastatic pancreatic cancer. Participants were split into two groups: those who had not yet received treatment and those who had already tried one type of chemotherapy. The goal was to see if thes…

This phase 2 trial tested two drugs, cabozantinib and pembrolizumab, in 21 people with metastatic pancreatic cancer that had worsened after standard treatment. The goal was to see if the combination could slow cancer growth. The study is complete, and results may help guide futur…

This study tested a new combination of drugs (ABT-888 plus chemotherapy) in 64 people with pancreatic cancer that had spread. The goal was to see if adding ABT-888, which blocks cancer cells from fixing DNA damage, could make chemotherapy work better and shrink tumors. The study …

This pilot study tested a highly targeted form of radiation called stereotactic body radiation therapy (SBRT) in 36 patients with pancreatic cancer that could not be removed by surgery or had come back after other treatments. The main goal was to see how safe the treatment was by…

This early-phase trial tested different combinations of immunotherapy drugs with standard chemotherapy for people with metastatic pancreatic cancer that had not been treated before. The main goal was to check safety and see if the combinations could shrink tumors or control the d…

This study tested a new experimental therapy using special immune cells (T cells) trained to attack proteins found on pancreatic cancer cells. The trial included 37 patients whose cancer had returned or not responded to standard treatment, or who chose not to have chemotherapy. T…

This early-phase study tested whether adding high-dose vitamin C (ascorbate) to standard chemotherapy and radiation is safe for people with pancreatic cancer. Sixteen adults with pancreatic cancer took part. The main goal was to see how many serious side effects occurred, with a …

This study looked at 119 people with locally advanced pancreatic cancer to see which radiation dose (lower or higher) works better when combined with chemotherapy. The goal was to find a dose that helps people live longer without causing too many side effects. Participants had no…

This study tested whether adding an immunotherapy drug (ipilimumab or nivolumab) to niraparib, a targeted therapy, can prevent advanced pancreatic cancer from growing. It enrolled 104 adults whose cancer had not worsened after platinum-based chemotherapy. The goal was to see how …

This early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …

This study tested a new treatment plan for people with advanced pancreatic cancer that has spread. It combined chemotherapy with drugs that change how genes work and boost the immune system. The goal was to see if this approach is safe and can help control the disease. 75 patient…

This completed phase I trial tested whether higher doses of a precise type of radiation called stereotactic body radiotherapy (SBRT) are safe for people with pancreatic cancer. Thirty patients with inoperable or locally advanced pancreatic cancer received five targeted radiation …

This study follows people with a significantly elevated risk of pancreatic cancer—due to inherited gene mutations or strong family history—who choose to undergo early detection testing. Participants receive endoscopic ultrasound (EUS) and MRI scans on an alternating schedule ever…

This trial evaluates a new biopsy needle (Micro-Tech FNB) used during endoscopic ultrasound to collect tissue samples from suspected pancreatic tumors. The goal is to see if this needle provides accurate diagnoses and yields enough high-quality tissue for genetic sequencing, whic…

This study tested whether a PET scan using a tracer called 18F-FAZA can measure low oxygen levels (hypoxia) in pancreatic cancer. Hypoxia can affect how the cancer grows and responds to treatment. 48 adults with pancreatic cancer received the scan, and researchers also collected …

This study used artificial intelligence to analyze CT scans and tissue samples from 247 pancreatic cancer patients. The goal was to create a model that predicts how the cancer will behave and how well patients will respond to chemotherapy. The model showed promising accuracy, but…

This early-phase study tested a new imaging agent called NMK89 in 10 people with pancreatic cancer. NMK89 is designed to attach to a protein (MUC5AC) found on these cancer cells and show up on PET scans. The main goal was to check if it is safe and how well it helps doctors see t…

This trial tests whether an ultrasound-guided injection of alcohol and a numbing agent around the celiac ganglia can relieve pain in people newly diagnosed with inoperable pancreatic cancer. Participants receive either the nerve block or a sham procedure, alongside standard pain …

This study tests a program called STRONG that gives pancreatic cancer patients extra support from a dietician and a Fitbit to track their food intake. The goal is to see if patients find the program helpful and easy to stick with while they are on chemotherapy. About 80 adults wi…

This study tested a home monitoring system for people with advanced pancreatic cancer receiving a strong chemotherapy called mFOLFIRINOX. The system tracked symptoms, activity, sleep, and weight using connected devices and an online platform. The goal was to see if early alerts c…

This study tested whether a remote nutrition coaching program is practical and well-liked by people with pancreatic cancer who are undergoing chemotherapy. Forty participants were asked to complete online food questionnaires and attend coaching sessions over 12 weeks. The goal wa…

This phase 2 trial looked at whether adding acupuncture and acupressure to oral cryotherapy (sucking on ice chips) can reduce nerve pain caused by oxaliplatin chemotherapy in people with gastrointestinal cancers. 78 patients were split into two groups: one got cryotherapy alone, …

This study looked at whether giving an additional anesthetic nerve block after pancreatic surgery helps patients use fewer opioid painkillers. 136 adults having open pancreatic surgery for cancer were randomly assigned to receive either one nerve block or a repeat block. The main…

This study tested a drug called telotristat ethyl in 23 people with advanced pancreatic cancer who had lost at least 10% of their body weight. The goal was to see if the drug could help them stabilize or gain weight by reducing bowel movements. Maintaining weight may help patient…

Researchers at Ghent University Hospital are studying whether MRI scans combined with computer models can measure the pressure inside tumors. High pressure in tumor tissue can block cancer drugs from reaching their target. The study enrolls 22 patients with pancreatic cancer or w…

This study investigates low-oxygen (hypoxic) areas within pancreatic tumors by giving patients a special marker before surgery. The marker highlights oxygen-deprived regions in the removed tumor tissue. Researchers will then analyze how these hypoxic zones relate to patient survi…

This study looked at whether an AI computer program could suggest cancer treatments that match what experts recommend. Researchers reviewed medical records of 30 people with stomach, colon, or pancreatic cancer. They entered key details into the AI and compared its suggestions to…

This study aimed to find biological markers (biomarkers) in pancreatic tumor cells and blood that could help predict how well a patient might respond to treatment. Researchers analyzed genetic and protein information from tumor samples collected via ultrasound-guided biopsy, as w…

This study looked at whether giving a short, strong dose of radiation right before surgery is possible for people with pancreatic cancer. Ten patients took part to see if the approach was safe and could help surgeons remove the tumor completely. The main goal was to check for com…

This study tested whether it is safe and possible to collect a blood sample from the portal vein (a major liver blood vessel) during a routine endoscopic ultrasound in 23 people with pancreatic cancer. The goal was to find and count circulating tumor cells (cancer cells in the bl…

This study examined small RNA molecules called microRNAs in tissue samples from 57 people with pancreatic cancer. The samples were collected during a routine endoscopic ultrasound procedure. Researchers aimed to see if certain microRNA patterns are linked to how aggressive the ca…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This completed study looked at whether a simple blood test (liquid biopsy) can find genetic markers that predict how well pancreatic cancer treatments work. Researchers analyzed DNA from tumors circulating in the blood of 420 patients with pancreatic cancer. The goal was to disco…

This study looked at 120 adults with breast, pancreatic, or biliary cancer to see if a new 3D measurement method (TDTP-RECIST) is better than the standard way (RECIST 1.1) for tracking tumor shrinkage before surgery. Researchers compared imaging results with actual tumor tissue r…

This study looked at 40 patients with pancreatic cancer to measure circulating tumor DNA (ctDNA) in blood from a vein near the pancreas and in the arm, as well as in fluid from the belly, during surgery. The goal was to see if these DNA levels could help predict how the disease p…

This study looked at whether organochlorine pesticides, which build up in body fat over time, are more common in people with pancreatic cancer. Researchers compared fat and urine samples from 56 patients undergoing surgery—some with pancreatic cancer and some without. The goal wa…

This study looked at whether two easy-to-use frailty checklists (FRAIL and FiND) can predict severe side effects from chemotherapy in adults aged 65 and older with gastrointestinal cancers. Researchers followed 84 patients who had already had surgery and were receiving standard c…

This completed study observed 178 patients with advanced cancer, chronic kidney failure, or chronic lung diseases to assess their palliative care needs and survival factors. Researchers used two scoring tools to evaluate when and how to best introduce palliative care alongside re…

This study looked at 35 people having surgery for pancreatic cancer to see if moving the tumor during the operation causes more cancer DNA to enter the bloodstream. Researchers took blood samples before, during, and after surgery to track these DNA levels. The goal was to better …

This study looked at whether it is safe and possible to grow mini-tumors (organoids) from pancreatic cancer samples in the lab. 60 patients with pancreatic cancer provided tumor tissue during surgery or biopsy. The goal was to see if these organoids could be used to test differen…

This study observed 799 adults with advanced or metastatic pancreatic cancer in Korea to see which chemotherapy treatments doctors actually use and why. Researchers tracked treatment choices, survival times, and quality of life. The goal was to understand real-world practice, not…

This completed study followed 44 adults who had Whipple surgery for cancers near the pancreas. Researchers measured changes in the remaining pancreas, including its size, metabolism, and nutrition levels, before surgery and at 3 and 6 months after. The goal was to learn how the b…